NCT02544425 (VIDL+ASCT) is a Phase 2 clinical trial of Etoposide in Extranodal NK-T-Cell Lymphoma, sponsored by Samsung Medical Center.

Who is sponsoring NCT02544425?

NCT02544425 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT02544425?

Interventions in NCT02544425: Etoposide, Ifosfamide, Dexamethasone, L-asparaginase, Busulfan, Melphalan.

What condition does NCT02544425 study?

NCT02544425 studies Extranodal NK-T-Cell Lymphoma.

Is NCT02544425 still recruiting?

NCT02544425 is currently status unknown. Last updated 22 October 2020.

Last reviewed 2020-10-22 · How we verify

NCT02544425: VIDL+ASCT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)

Status unknown Phase 2 Last updated 22 October 2020

What this trial tests

Phase 2 trial testing Etoposide in Extranodal NK-T-Cell Lymphoma in 27 participants. Status unknown.

Timeline

21 February 2016

Primary endpoint
31 August 2021

30 November 2021

Quick facts

Lead sponsor	Samsung Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	21 February 2016
Primary completion	31 August 2021
Estimated completion	30 November 2021
Sites	2 locations across South Korea

Drugs / interventions tested

Etoposide (etoposide) — full drug profile →
Ifosfamide (IFOSFAMIDE) — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →
L-asparaginase
Busulfan — full drug profile →
Melphalan

Conditions studied

Extranodal NK-T-Cell Lymphoma — all drugs for Extranodal NK-T-Cell Lymphoma →

Sponsor

Samsung Medical Center

Who can join

Adults 19 to 65, any sex, with Extranodal NK-T-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open-labeled, multicenter phase II study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation in patients with stage III/IV extranodal NK/T-cell Lymphoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma.
Song GY, Yoon DH, Suh C, Moon JH, et al · · 2021 · cited 14× · PMID 33277620 · DOI 10.1038/s41409-020-01160-2

Verify or expand the search:

Other trials of Etoposide

Trials testing the same drug.

NCT06738368 — Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin · Phase 2 · recruiting
NCT06406465 — A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity · Phase 2 · recruiting
NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm · Phase 1, PHASE2 · recruiting
NCT07321912 — Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma · Phase 2 · not yet recruiting
NCT07224100 — Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosom · Phase 2 · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02544425 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 22 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02544425.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing